Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease

Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of mortality. SSc-ILD is variable: from limited forms (with asymptomatic patients) to extensive lesions. Disease course in SSc-ILD is also highly variable: patients can experience stable disease, slow or fast progression. Investigators performed unsupervised clustering analysis to classify SSc-ILD according to elementary radiological lesions on HRCT scan.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Systemic Sclerosis Connective Tissue Diseases Interstitial Lung Disease Lung Diseases Lung Diseases, Interstitial Respiratory Tract Diseases Scleroderma, Systemic Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Central Hospital

Nancy, France

Location status: Recruiting

Location contact

Paul DECKER, MD

CONTACT

[email protected]

Roland JAUSSAUD, Pr

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with systemic sclerosis according to 2013 ACR/EULAR criteria
Patients with interstitial lung disease on HRCT chest

Exclusion criteria

Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)

Treatment and study plan

Primary outcomes

HRCT scan variables

Time frame: baseline (J0)

HRCT scan variables included in hierarchical agglomerative clustering (HAC) analysis

Study contacts

Contact information is provided by the study sponsor or research team.

Paul DECKER, MD

CONTACT

[email protected]

+33383157240

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Unsupervised Clustering Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease

Acronym: LUNGSCLEROCT

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Aug 1, 2022
Registry last updated: Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting